{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(3)"],"submitter":["Loibl S"],"pubmed_abstract":["<h4>Background</h4>Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, 'SOFIA'.<h4>Patients and methods</h4>INCLUSION CRITERIA WERE: HER2 negative, cT3, cT4 or cT2 cN+, M0 primary breast cancer. Patients received 4 × epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) (EC) intravenously (i.v.) in 3-weekly cycles followed or preceded by 12 weeks of paclitaxel (Pw) 80 mg/m(2). In cohort 1, sorafenib started at 800 mg daily with chemotherapy. An initial daily sorafenib dose of 200 mg was escalated, based on individual toxicities, every 3 weeks in cohort 2 (starting with EC) and every 2 weeks in cohort 3 (starting with Pw). The primary objective was to identify the most feasible regimen; se"],"journal":["Breast care (Basel, Switzerland)"],"pagination":["169-74"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4132235"],"repository":["biostudies-literature"],"pubmed_title":["Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA."],"pmcid":["PMC4132235"],"pubmed_authors":["Eidtmann H","Mehta K","Harbeck N","Rokitta D","Schwedler K","Schrader I","Warm M","von Minckwitz G","Gerber B","Loibl S","Fuhr U","Conrad B","Wullner M"],"additional_accession":[]},"is_claimable":false,"name":"Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.","description":"<h4>Background</h4>Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, 'SOFIA'.<h4>Patients and methods</h4>INCLUSION CRITERIA WERE: HER2 negative, cT3, cT4 or cT2 cN+, M0 primary breast cancer. Patients received 4 × epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) (EC) intravenously (i.v.) in 3-weekly cycles followed or preceded by 12 weeks of paclitaxel (Pw) 80 mg/m(2). In cohort 1, sorafenib started at 800 mg daily with chemotherapy. An initial daily sorafenib dose of 200 mg was escalated, based on individual toxicities, every 3 weeks in cohort 2 (starting with EC) and every 2 weeks in cohort 3 (starting with Pw). The primary objective was to identify the most feasible regimen; se","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jul","modification":"2025-04-04T20:45:22.49Z","creation":"2019-03-27T01:34:00Z"},"accession":"S-EPMC4132235","cross_references":{"pubmed":["25177258"],"doi":["10.1159/000363430"]}}